Canopy Biosciences

About:

Canopy Biosciences aims to accelerate the commercialization of life science reagent tools and services through in-licensing.

Website: http://www.canopybiosciences.com

Top Investors: Ampersand Capital Partners, Archangels, BioGenerator, Missouri Technology Corporation, Kingdom Capital

Description:

Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University. Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.